"HIV-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
MeSH Number(s)
B04.820.650.589.650.350.400
B04.909.777.731.589.650.350.400
Concept/Terms
HIV-1- HIV-1
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1
- HIV-I
- Human immunodeficiency virus 1
Below are MeSH descriptors whose meaning is more general than "HIV-1".
Below are MeSH descriptors whose meaning is more specific than "HIV-1".
This graph shows the total number of publications written about "HIV-1" by people in Harvard Catalyst Profiles by year, and whether "HIV-1" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 72 | 4 | 76 |
| 1994 | 81 | 8 | 89 |
| 1995 | 78 | 6 | 84 |
| 1996 | 102 | 4 | 106 |
| 1997 | 110 | 10 | 120 |
| 1998 | 130 | 9 | 139 |
| 1999 | 130 | 9 | 139 |
| 2000 | 128 | 22 | 150 |
| 2001 | 101 | 32 | 133 |
| 2002 | 108 | 19 | 127 |
| 2003 | 107 | 22 | 129 |
| 2004 | 108 | 20 | 128 |
| 2005 | 125 | 17 | 142 |
| 2006 | 128 | 31 | 159 |
| 2007 | 127 | 23 | 150 |
| 2008 | 121 | 36 | 157 |
| 2009 | 137 | 33 | 170 |
| 2010 | 158 | 33 | 191 |
| 2011 | 132 | 41 | 173 |
| 2012 | 168 | 37 | 205 |
| 2013 | 163 | 32 | 195 |
| 2014 | 145 | 34 | 179 |
| 2015 | 130 | 26 | 156 |
| 2016 | 115 | 25 | 140 |
| 2017 | 92 | 44 | 136 |
| 2018 | 112 | 28 | 140 |
| 2019 | 87 | 43 | 130 |
| 2020 | 105 | 43 | 148 |
| 2021 | 99 | 25 | 124 |
| 2022 | 101 | 7 | 108 |
| 2023 | 52 | 0 | 52 |
Below are the most recent publications written about "HIV-1" by people in Profiles.
-
Persistence of intact HIV-1 proviruses in the brain during antiretroviral therapy. Elife. 2023 Nov 08; 12.
-
Inadequate structural constraint on Fab approach rather than paratope elicitation limits HIV-1 MPER vaccine utility. Nat Commun. 2023 Nov 08; 14(1):7218.
-
Natural killer cell responses during SARS-CoV-2 infection and vaccination in people living with HIV-1. Sci Rep. 2023 11 03; 13(1):18994.
-
Predicted resistance to broadly neutralizing antibodies (bnAbs) and associated HIV-1 envelope characteristics among seroconverting adults in Botswana. Sci Rep. 2023 10 24; 13(1):18134.
-
Biphasic decay of intact SHIV genomes following initiation of antiretroviral therapy complicates analysis of interventions targeting the reservoir. Proc Natl Acad Sci U S A. 2023 Oct 24; 120(43):e2313209120.
-
Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use. J Antimicrob Chemother. 2023 10 03; 78(10):2489-2495.
-
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial. Lancet HIV. 2023 10; 10(10):e653-e662.
-
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial. Lancet HIV. 2023 Nov; 10(11):e703-e712.
-
Alterations in gp120 glycans or the gp41 fusion peptide-proximal region modulate the stability of the human immunodeficiency virus (HIV-1) envelope glycoprotein pretriggered conformation. J Virol. 2023 09 28; 97(9):e0059223.
-
Immune Modulation of HIV-1 Reservoir Size in Early-Treated Neonates. J Infect Dis. 2023 08 11; 228(3):281-286.